Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Resets Aduhelm Expectations, Expects Longer, Slower Path To Significant Sales

Best Case Scenario: Meaningful Patient Access Over Time

Executive Summary

The company reported $1m in Q4 sales of its Alzheimer’s drug. Biogen expects Aduhelm to make a minimal contribution to full-year 2022 revenues, which will total about $1bn less than in 2021. 

You may also be interested in...



Biogen’s Aduhelm Competitors Boosted By Final CMS Coverage Decision

The Center for Medicare and Medicaid Services’ final decision on Medicare coverage favors anti-amyloid antibodies approved for Alzheimer’s disease based on efficacy rather than biomarker data.

Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement

The companies amended the terms of their Alzheimer’s collaboration to give Biogen full decision-making control over Aduhelm immediately. Eisai’s 50% share of profits and losses from the drug switches to a 2% royalty in 2023. The partners’ agreement for Eisai-led lecanemab remains intact.

Lilly Waiting On Phase III Data For Donanemab

Lilly no longer plans to complete an accelerated approval submission for Alzheimer’s candidate donanemab during Q1 following the CMS draft coverage decision for amyloid-targeting therapies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel